2024-09-08 - Analysis Report
##  REGEN Stock Analysis Report

**Company Overview:** Regeneron Pharmaceuticals, Inc. (REGEN) is a biotechnology company focused on developing and commercializing life-transforming medicines for serious diseases. 

**1. Performance vs. S&P 500 (VOO):**

* **Cumulative Return:** REGN: 147.14%, VOO: 81.34%. 
* **Difference:** REGN has outperformed VOO by 65.8%. This places REGN at the 92.31 percentile of its historical performance compared to VOO.

**2. Recent Price Action:**

* **Closing Price:** $1131.5
* **5-Day Moving Average:** $1162.99
* **20-Day Moving Average:** $1173.88
* **60-Day Moving Average:** $1100.42

This indicates a short-term downtrend as the price is below all moving averages.

**3. Technical Indicators:**

* **RSI:** 33.89. This suggests the stock is currently oversold, potentially signaling a possible rebound.
* **PPO:** -0.83. This indicates a negative momentum, implying further downside potential.
* **Delta_Previous_Relative_Divergence:** -7.69. This shows a recent decline in relative performance against the broader market.
* **Expected Return:** 5.77%. This represents the potential maximum return over a 5-year period for a current investment. 

**4. Recent Earnings and Outlook:**

| Date | EPS | Revenue | 
|---|---|---|
| 2024-08-01 | 13.25 | 3.55 B$ |
| 2024-05-02 | 6.7 | 3.15 B$ |
| 2023-11-02 | 9.48 | 3.36 B$ |
| 2023-08-03 | 9.05 | 3.16 B$ |
| 2024-08-01 | 9.05 | 3.16 B$ |

The latest earnings report for Q2 2024 was $13.25 EPS, exceeding expectations by a significant margin. However, revenue missed analysts' estimates. Despite the mixed results, the company continues to demonstrate strong growth in core businesses and maintains a robust pipeline.

**5. Summary:**

REGEN has historically outperformed the S&P 500 significantly and currently stands at a 92.31 percentile in relative performance. However, recent price action shows a short-term downtrend with the stock trading below all moving averages. Technical indicators suggest potential for a rebound, with an RSI indicating oversold conditions.  Despite a mixed earnings report, the company continues to demonstrate strong growth potential and a robust pipeline.

**6. Recommendation:**

While the stock is currently oversold and may be ripe for a rebound, the recent decline in relative performance and negative momentum require further investigation. Consider monitoring the stock's price action and technical indicators for a more definite buy signal. The company's strong fundamentals and future prospects suggest that REGN remains a valuable long-term investment option. 
